Evaro lands $25M Series A to bring regulated NHS care into consumer apps
UK healthtech Evaro has raised $25 million in a Series A round to expand its healthcare-as-a-service platform, which enables consumer brands to embed regulated clinical services—such as consultations, prescriptions and follow-up care—directly inside their apps.
The round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI. The company says the new capital will be used to broaden its clinical offering beyond its current focus areas, deepen partnerships, and continue improving its API-first integration layer for third-party apps.
Pressure on primary care creates an opening for new delivery models
Evaro is positioning itself at the intersection of rising patient demand for convenience and strict UK healthcare regulation. The company points to prolonged waits for primary care as a key driver: in 2024, more than 20 million people in the UK reportedly waited over a month to see a GP. In parallel, consumer health and lifestyle apps have built large audiences and habitual engagement, but most cannot offer regulated clinical services without the appropriate licensing, governance and pharmacy infrastructure.
That gap—high distribution via consumer apps but limited ability to provide compliant healthcare—has become an attractive opportunity for platforms that can supply the “clinical stack” as an embedded service. Evaro says its approach is designed to make healthcare feel as seamless as other regulated digital services, such as online banking, while still meeting clinical and regulatory requirements.
A healthcare-as-a-service platform built for brands
Founded in 2018, Evaro was established by emergency physician Dr Thuria Wenbar (CEO) and pharmacist-researcher Dr Oskar Wenbar (CMO). The founders say the company emerged from firsthand experience of patients struggling to access timely care for routine conditions—cases that could often be handled safely through remote pathways if properly designed and governed.
At the core of the product is an API-first platform intended to integrate into partner apps quickly—Evaro says deployments can be live in as little as two weeks. The company describes its service as a full clinical stack, including:
- asynchronous consultations,
- NHS GP record access,
- remote diagnostics,
- automated dispensing, and
- aftercare and follow-up.
Evaro says it currently supports treatment pathways for more than 80 conditions and reports a 4.5 rating on Trustpilot. It also claims to have already helped two million patients access care through its partner channels.
Regulatory compliance as a product differentiator
One of the company’s central claims is that it has built the licensing and compliance framework needed for consumer brands to offer regulated healthcare legally, without building their own clinical operations. Evaro says it holds simultaneous approvals across major UK healthcare regulators and systems, including NHS linkage as well as CQC and GPhC licensing, describing a total of seven approvals.
In practice, this regulatory posture is what allows consumer brands to embed healthcare journeys—consultation through to prescription fulfilment and aftercare—within their own user experiences. The company’s existing partner examples include Clue and Lovehoney, which have large, loyal user bases but historically have not been able to provide regulated clinical services directly inside their products.
Competitive landscape: telehealth providers vs white-label infrastructure
The UK digital health market includes well-known telehealth and online pharmacy brands such as Babylon, Push Doctor and Pharmacy2U. However, Evaro argues its differentiation is not simply delivering care under its own brand, but offering white-label healthcare-as-a-service that consumer apps can embed as a native feature.
This “infrastructure layer” approach aims to let brands keep the customer relationship and user experience, while Evaro provides the regulated clinical operations and technology backbone. In a market where user acquisition can be expensive and attention is fragmented, partnering with established consumer apps offers an alternative distribution path—provided compliance and clinical governance can be maintained.
How Evaro plans to use the new funding
With the Series A secured, Evaro says it will expand beyond women’s and men’s health into longevity and advanced diagnostics, while also growing its partner network across consumer brands, healthcare organisations and employer benefits programmes. The company also plans continued investment in its API and integration tooling to reduce friction for partners and improve end-to-end patient journeys.
As healthcare systems face capacity constraints and patients increasingly expect digital-first experiences, Evaro is betting that regulated care delivered inside the apps people already use can become a scalable complement to traditional access routes—if it can maintain clinical quality, compliance and reliable fulfilment at growing volume.
Related
